References
1 . Pruszkowski A, Bodemer C, Fraitag S et al. Neonatal and
infantile erythrodermas: a retrospective study of 51 patients. Arch
Dermatol 2000; 136: 875–880.
2 . Chavanas S, Bodemer C, Rochat A et al. Mutations in SPINK5,
encoding a serine protease inhibitor, cause Netherton syndrome. Nat
Genet 2000; 25: 141–142.
3 . The Human Gene Mutation Database (HGMD).
https://www.hgmd.cf.ac.uk/ac/gene.php?gene=SPINK5 (20 March 2023, date
last accessed).
4 . Petrova E, Hovnanian A. Advances in understanding of
Netherton syndrome and therapeutic implications. Expert Opin Orphan
Drugs 2020; 8: 455–487.
5 . Hovnanian A. Netherton syndrome: skin inflammation and
allergy by loss of protease inhibition. Cell Tissue Res 2013; 351:
289–300.
6 . Bitoun E, Micheloni A, Lamant L et al. LEKTI proteolytic
processing in human primary keratinocytes, tissue distribution and
defective expression in Netherton syndrome. Hum Mol Genet 2003; 12:
2417–2430.
7 . Srinivas SM, Hiremagalore R, Suryanarayan S et al. Netherton
syndrome with pili torti. Int J Trichology 2013; 5: 225–226.
8 . Huang B, Liu R, Wang P et al. CD8+CD57+ T cells exhibit
distinct features in human non-small cell lung cancer. J Immunother
Cancer 2020; 8: e000639.
9 . Nouwen AEM, Schappin R, Nguyen NT et al. Outcomes of
Systemic Treatment in Children and Adults With Netherton Syndrome: A
Systematic Review. Front Immunol 2022; 13: 864449.
10 . Broderick C, Kobayashi S, Suto M et al. Intravenous
immunoglobulin for the treatment of Kawasaki disease. Cochrane Database
Syst Rev 2023; 2023: CD014884.
11 . Eränkö E, Ilander M, Tuomiranta M et al. Immune cell
phenotype and functional defects in Netherton syndrome. Orphanet J Rare
Dis 2018; 13: 213.
12 . Tangye SG, Al-Herz W, Bousfiha A et al. Human Inborn Errors
of Immunity: 2022 Update on the Classification from the International
Union of Immunological Societies Expert Committee. J Clin Immunol 2022;
42: 1473–1507.
13 . van der Voort EAM, Prens EP. Netherton syndrome with
multiple non-melanoma skin cancers. Acta Derm Venereol 2013; 93:
727–728.
14 . Pontone M, Giovannini M, Filippeschi C et al. Biological
treatments for pediatric Netherton syndrome. Front Pediatr 2022; 10:
1074243.
15. Klein E, Hahn GM, Solomon JA, et al. Explorations of antimitotic
agents in the treatment of a congenital disease, ichthyosis linearis
circumflexa. J Surg Oncol. 1979;11:85-8
16. Suga Y, Tsuboi R, Hashimoto Y, et al. A case of ichthyosis linearis
circumflexa successfully treated with topical tacrolimus. J Am Acad
Dermatol. 2000;42:520-2
17 . Nouwen AEM, Schappin R, Nguyen NT et al. Outcomes of
Systemic Treatment in Children and Adults With Netherton Syndrome: A
Systematic Review. Front Immunol 2022; 13: 864449.
18 . Clinical Trials register - Search for Netherton Syndrome.
https://www.clinicaltrialsregister.eu/ctr-search/search?query=Netherton+Syndrome
(20 March 2023, date last accessed).